All In Biotech

Drug Trial Radar · NCT00909181

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment With Topically Administered Oxybutynin Gel in Patients With Urinary Frequency, and Urge and Mixed Urinary Incontinence With a Predominance of Urge Incontinence Episodes With an Open-Label Extension

Last checked: Nov 20, 2026Latest source record: Jul 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 626 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

626

Actual

Start

Mar 2009

Primary completion

Jul 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Antares Pharma Inc.Industry
Sponsor type
Industry
First posted
May 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel. The objective of the open-label extension is to evaluate the extended safety and skin-irritation profile of topically administered oxybutynin gel. The hypothesis is that topically administered oxybutynin gel will decrease (compared to placebo) the number of incontinence episodes per week, average daily urinary frequency, and urinary urgency; increase average urinary void volume; and improve patient quality of life.

Conditions

  • Urge Urinary Incontinence
  • Urinary Frequency

Interventions

  • OxybutyninDrug

    Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment. Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

  • PlaceboDrug

    Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment. Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12Time frame: 12 weeks

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Laguna Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Farmington, Connecticut

  • Site not named

    New Britain, Connecticut

  • Site not named

    New Port Richey, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    Sandy Springs, Georgia

  • Site not named

    Stockbridge, Georgia

  • Site not named

    Evanston, Illinois

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Annapolis, Maryland

  • Site not named

    Towson, Maryland

  • Site not named

    Watertown, Massachusetts

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Saginaw, Michigan

  • Site not named

    Chesterfield, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Brooklyn, New York

  • Site not named

    Endwell, New York

  • Site not named

    Kingston, New York

  • Site not named

    Poughkeepsie, New York

  • Site not named

    Williamsville, New York

  • Site not named

    Cary, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Harrisburg, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Salisbury, North Carolina

  • Site not named

    Wilmington, North Carolina

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.